People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Gen9, Inc. | — | Biotechnology | Series B | $52.1M | $992.2M | 2013 |
| Seahorse Bioscience Inc | — | Biotechnology | Series A | $20.7M | $410.2M | 2012 |
| Some Other Me, LLC | — | Other | Series A | $10.0M | $25.0M | — |
| Formation Metals Inc | — | Other | Series A | $8.1M | $7.6M | 2009 |
| Kimberly Akimbo Ltd Liability Co | — | Other | Series A | $7.0M | $61.3M | 2022 |
| Transformativemed Inc. | — | Other Technology | Series A | $6.2M | $16.1M | 2018 |
| Purpose Broadway Ltd Liability Co | — | Other | Series A | $5.3M | $20.6M | 2024 |
| Face to Face Broadway LLC | — | Other | Series A | $5.2M | $79.2M | 2016 |
| Invizeon Corp | — | Other Technology | Seed | $4.7M | $4.4M | 2009 |
| Topdog 20th Ltd Liability Co | — | Other | Seed | $2.5M | $22.3M | 2022 |
| Next to Normal LLC | — | Other | Seed | $1.9M | $34.9M | 2009 |
| Forager1, Inc. | — | Other | Pre-Seed | $271K | $5.9M | 2020 |
David Stone at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Stone on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Rosen | 1 | 13 |
| Peter Weiss | 1 | 9 |
| Fouad Azzam | 1 | 8 |
| Steven Young | 1 | 6 |
| Paul Manning | 1 | 6 |
| Harry Wilcox | 1 | 6 |
| Robert J. Quinn | 1 | 4 |
| Joseph Keegan | 1 | 4 |
| Jeremy Wertheimer | 1 | 4 |
| Stanley Rose | 1 | 4 |
| Robert Quinn | 1 | 3 |
| Joel Mezistrano | 1 | 3 |
| James B. Engdahl | 1 | 3 |
| Joseph Jacobson | 1 | 3 |
| Weili Dai | 1 | 3 |
| Lawrence Silverstein | 1 | 2 |
| Jay Teich | 1 | 2 |
| Stephen Jurvetson | 1 | 2 |
| Scott A. Hean | 1 | 2 |
| Jeffrey Hurst | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.